Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | PRF1 | P14222 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12319341 | 0.87 | GLO1 (0.41) | SLC40A1GLO1CA1CA2MMP2 | |
| SCHEMBL1824894 | 0.85 | CA1 (0.42) | TYK2BTKCA1CA2PDE3A | |
| SCHEMBL1825015 | 0.83 | PDE4A (0.43) | CA1CA2PDE3A | |
| SCHEMBL1825541 | 0.82 | ALDH1A1 (0.45) | CA1CA2PDE3A | |
| SCHEMBL1827272 | 0.81 | CA1 (0.41) | BTKCA1CA2 | |
| SCHEMBL13035427 | 0.81 | CA1 (0.52) | CA1CA2 | |
| SCHEMBL1823409 | 0.81 | CA1 (0.43) | SLC40A1TYK2BTKCA1CA2 | |
| SCHEMBL12655356 | 0.80 | SLC40A1 (0.46) | SLC40A1GLO1BRAFTYK2JAK2 | |
| SCHEMBL12655496 | 0.79 | ACLY (0.43) | SLC40A1CA1CA2PDE3AMETAP2 | |
| SCHEMBL2406838 | 0.78 | CA1 (0.46) | BTKCA1CA2PDE3AKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | SLC40A1 1763/4885GLO1 4022/4885BRAF 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.